ライフサイエンスコーパス: dabigatran

1 strointestinal bleeding among users naive to dabigatran.

2 loped to reverse the anticoagulant effect of dabigatran.

3 safely reversed the anticoagulant effect of dabigatran.

4 n antidote to rapidly reverse the effects of dabigatran.

5 r apixaban and rivaroxaban and <120 days for dabigatran.

6 vo that is induced by the thrombin inhibitor dabigatran.

7 costly and less effective than warfarin and dabigatran.

8 erences in use, safety, and effectiveness of dabigatran.

9 a lower risk of intracranial hemorrhage with dabigatran.

10 oped to reverse the anticoagulant effects of dabigatran.

11 associated with greater patient adherence to dabigatran.

12 corresponding undetectable levels of unbound dabigatran.

13 cluded atrial fibrillation for which he took Dabigatran.

14 herapy, and compared with high- and low-dose dabigatran.

15 higher gastrointestinal bleeding rates with dabigatran.

16 care and 22 (13%) of 176 children receiving dabigatran.

17 jor bleeding when compared with warfarin and dabigatran.

18 initiated on VKA, rivaroxaban, apixaban, and dabigatran.

19 2-2.70]; and low-molecular-weight heparin vs dabigatran 0.67 [0.20-1.82]).

20 in IRR 0.78 [95% CrI 0.47-1.08]; warfarin vs dabigatran 0.88 [0.59-1.36]; factor Xa vs low-molecular-

21 compared with warfarin (0.25 [0.07-0.76]) or dabigatran (0.24 [0.07-0.77]).

22 for dabigatran 150 mg (0.43, 0.26-0.72) and dabigatran 110 mg (0.36, 0.22-0.61) were also observed.

23 0.90), edoxaban 30 mg (0.48, 0.42-0.56), and dabigatran 110 mg (0.81, 0.71-0.94) significantly reduce

24 with dabigatran 150 mg (1.78, 1.35-2.35) and dabigatran 110 mg (1.40, 1.04-1.90) and lower intracrani

25 2,025 (90%) and 231 (10%) CKD patients took dabigatran 110 mg and 150 mg twice daily, respectively.

26 ic event rates were similar for warfarin and dabigatran 110 mg regardless of the presence of VHD (HR,

27 For patients receiving dabigatran 110 mg, major bleed rates were lower than for

28 Men and women who filled a prescription for dabigatran (110 and 150 mg bid) were compared with match

29 ose rivaroxaban (10 to 15 mg once daily) and dabigatran (110 mg twice daily), respectively.

30 Any bleeding occurred in 200 dabigatran (15.6%) and 285 warfarin (22.1%; hazard ratio

31 We identified 17 eligible studies for dabigatran, 15 for rivaroxaban, and 4 for apixaban.

32 of Long-Term Anticoagulant Therapy) compared dabigatran 150 and 110 mg twice daily with warfarin in 1

33 Intracranial bleeds and death rates for dabigatran 150 and 110 mg were lower compared with warfa

34 wer intracranial bleeding risks than VKA for dabigatran 150 mg (0.43, 0.26-0.72) and dabigatran 110 m

35 higher gastrointestinal bleeding risks with dabigatran 150 mg (1.78, 1.35-2.35) and dabigatran 110 m

36 jor bleeding than with VKA was observed with dabigatran 150 mg (odds ratio, 1.18; 95% confidence inte

37 stroke or systemic embolism were lower with dabigatran 150 mg and similar with 110 mg twice daily co

38 n for ischemic stroke/systemic embolism with dabigatran 150 mg twice daily ranged from <10% in 20% of

39 ere most pronounced in patients treated with dabigatran 150 mg twice daily, whereas the association o

40 0.99 without VHD), and major bleed rates for dabigatran 150 mg were similar to those for warfarin in

41 For dabigatran 150 mg, stroke/systemic embolic event rates w

42 In the dabigatran 150-mg twice daily subgroup, the magnitude of

43 Dabigatran (150 mg twice daily) has been associated with

44 Dabigatran-150 mg had a significantly greater hazard of

45 In pooled analyses, dabigatran-150 mg was not superior to warfarin in preven

46 d across the 3 drugs (rivaroxaban: 20 mg QD, dabigatran: 150 mg BID, or warfarin) using 3-way propens

47 Dabigatran (20 and 200 nM) inhibits (50 and 93%) clot-bo

48 All were on DOACs (333 rivaroxaban, 285 dabigatran, 281 apixaban, and 1 edoxaban).

49 nitiating vitamin K antagonists (VKA) (42%), dabigatran (29%), rivaroxaban (13%), or apixaban (16%) w

50 age, 74.7 years [SD, 10.8]; men, 55.8%; NOAC dabigatran, 45347 patients; rivaroxaban, 54006 patients;

51 olic events occurred in 4 subjects receiving dabigatran (50%) and in 1 receiving phenprocoumon (13%;

52 Most patients treated with dabigatran 75 mg twice daily appeared not to have severe

53 In the subgroup treated with dabigatran 75 mg twice daily, there was no difference in

54 -PA within 4.5 hours, 251 were taking NOACs (dabigatran 87, rivaroxaban 129, and apixaban 35) before

55 OACs (rivaroxaban 7,572, apixaban 1,066, and dabigatran 96).

56 study evaluates whether anticoagulation with dabigatran, a clinically approved oral direct thrombin i

57 In contrast, treatment with dabigatran, a direct thrombin inhibitor, limited HFD-ind

58 For dabigatran, a normal thrombin time excludes clinically r

59 umab showed a rapid and complete reversal of dabigatran activity in nearly all patients presenting wi

60 Dabigatran adherence (intensity of drug use during thera

61 After multivariable adjustment, dabigatran adherence across sites varied by a median odd

62 ciation between pharmacist-led education and dabigatran adherence was not statistically significant (

63 ixaban, edoxaban (antifactor Xa agents), and dabigatran (an antithrombin agent) were noninferior and

64 July 1, 2010 and March 31, 2012 with use of dabigatran and at least one gastrointestinal bleeding ep

65 Dabigatran and idarucizumab, its reversal agent, are ren

66 The possible relationship between dabigatran and myocardial infarction warrants further in

67 Patients treated with dabigatran and planned for an invasive procedure were el

68 matoma formation in mice anticoagulated with dabigatran and reduces mortality.

69 Dabigatran and rivaroxaban are new oral anticoagulants t

70 Dabigatran and rivaroxaban new users were matched to VKA

71 o describe the point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis

72 Since then, dabigatran and rivaroxaban use in the atrial fibrillatio

73 More dialysis patients are being started on dabigatran and rivaroxaban, even when their use is contr

74 NOACs, particularly dabigatran and rivaroxaban, may be associated with lower

75 terval, 0.72-1.69) risk was observed between dabigatran and VKA new users.

76 ence in GI incidence rate between periods of dabigatran and warfarin (IRR = 0.99, 95% CI 0.75-1.31).

77 Dabigatran and warfarin have been compared for the treat

78 Dabigatran and warfarin were taken by 7,702 and 7,885 NV

79 n patients taking rivaroxaban, compared with dabigatran and warfarin, seems to be limited to men, whe

80 0 [34%] to standard of care and 177 [66%] to dabigatran) and included in the analyses.

81 tients were randomised 1:2 (standard of care:dabigatran) and stratified by age (12 to <18 years, 2 to

82 population was composed of 19 713 VKA, 8443 dabigatran, and 4651 rivaroxaban new users.

83 78%) for apixaban, 60% (95% CI, 52%-68%) for dabigatran, and 70% (95% CI, 64%-75%) for rivaroxaban.

84 t oral anticoagulants-rivaroxaban, apixaban, dabigatran, and edoxaban-is noninferior to warfarin (abs

85 ts; 4 anticoagulants (warfarin, rivaroxaban, dabigatran, and enoxaparin) and 5 diabetes agents (insul

86 All dabigatran- and rivaroxaban-treated patients were matche

87 Complete reversal of the dabigatran anticoagulant effect occurred within minutes

88 y 2016 in the RE-VERSE AD study (Reversal of Dabigatran Anticoagulant Effect With Idarucizumab), a pr

89 (Reversal of Dabigatran Anticoagulant Effect With Idarucizumab; NCT02

90 Dabigatran anticoagulation also prevented AD-related ast

91 rimary end point was the maximum reversal of dabigatran anticoagulation within 4 hours after administ

92 nized monoclonal antibody fragment, reverses dabigatran anticoagulation.

93 treated with one of the NOACs (rivaroxaban, dabigatran, apixaban) or VKA were identified between Feb

94 n factors of DBS to plasma concentrations of dabigatran, apixaban, and rivaroxaban were 1.81, 1.59, a

95 meta-analysis of randomized trials of DOACs (dabigatran, apixaban, rivaroxaban, and edoxaban) for eff

96 Our protocol for perioperative management of dabigatran appears to be effective and feasible.

97 st oral anticoagulant agents rivaroxaban and dabigatran are superior to warfarin for efficacy and saf

98 actors associated with improved adherence to dabigatran are unknown.

99 ess and safety study of standard-dose NOACs (dabigatran at 150 mg twice daily, rivaroxaban at 20 mg o

100 ctiveness and safety of standard-dose NOACs (dabigatran at 150 mg twice daily, rivaroxaban at 20 mg o

101 o catalytic inactive thrombin incubated with dabigatran at 20-fold higher therapeutic concentration r

102 Here, we report that dabigatran at clinically relevant concentrations is an e

103 The timing of the last dose of dabigatran before the procedure was based on the creatin

104 Men benefit from lower bleeding rates with dabigatran compared with warfarin.

105 is was lower for treatment with apixaban and dabigatran compared with warfarin.

106 direct oral anticoagulants (rivaroxaban and dabigatran), compared to each other and to warfarin amon

107 hemic events was inversely related to trough dabigatran concentrations (p = 0.045), with age and prev

108 s starting warfarin therapy, those receiving dabigatran did not have significantly different rates of

109 nt, target-specific oral anticoagulants like dabigatran do not.

110 r, with the CKD-EPI and MDRD equations, both dabigatran dosages displayed significantly lower rates o

111 omen filled more prescriptions for the lower dabigatran dose compared with men (adjusted OR, 1.35; 95

112 tive reduction in major bleeding with either dabigatran dose compared with warfarin was greater in pa

113 Dabigatran dose was 110 and 75 mg BID in patients with n

114 ng algorithm, and the efficacy and safety of dabigatran dosed according to that algorithm versus stan

115 An age-adjusted and weight-adjusted dabigatran dosing algorithm was appropriate in children

116 to study the appropriateness of a paediatric dabigatran dosing algorithm, and the efficacy and safety

117 parinux) was compared with a paediatric oral dabigatran dosing regimen (an age-adjusted and weight-ad

118 reatment using DOACs (rivaroxaban, apixaban, dabigatran, edoxaban).

119 gonist oral anticoagulants (NOACs) apixaban, dabigatran, edoxaban, and rivaroxaban are administered i

120 ct oral anticoagulants (DOACs; ie, apixaban, dabigatran, edoxaban, and rivaroxaban) are at least as e

121 at have reached the market, ximelagatran and dabigatran etexilat, are double prodrugs with low bioava

122 Dabigatran etexilate (DE) dose-dependently prolonged dil

123 during long-term treatment with warfarin or dabigatran etexilate (DE) in patients enrolled in the RE

124 ran were determined in patients treated with dabigatran etexilate 110 mg twice daily (bid) or 150 mg

125 All participants received oral dabigatran etexilate 220 mg twice daily for 3 days and a

126 ) was administered about 2 h after the final dabigatran etexilate dose.

127 Undetermined Source) and the RE-SPECT ESUS (Dabigatran Etexilate for Secondary Stroke Prevention in

128 o describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolis

129 fect curve from 2 h to 12 h (AUEC2-12) after dabigatran etexilate ingestion on days 3 and 4.

130 Dabigatran etexilate is a direct oral anticoagulant with

131 In particular, the potential dual benefit of dabigatran etexilate might be reconsidered for patients

132 r abciximab) or anticoagulants (antithrombin dabigatran etexilate or anti-vitamin K acenocoumarol) wa

133 ype littermates were treated for 1 year with dabigatran etexilate or placebo.

134 o (infusion site haematoma), and four during dabigatran etexilate pretreatment (three haematuria and

135 Dabigatran etexilate protected 75% of rats against IE du

136 The efficacy and safety of dabigatran etexilate were demonstrated in the RE-LY (Ran

137 on of Long-Term Anticoagulation Therapy With Dabigatran Etexilate) (n=11 955 in derivation cohort, n=

138 We included the phase 3 trials that compared dabigatran etexilate, rivaroxaban, apixaban, or edoxaban

139 rticipants who received at least one dose of dabigatran etexilate.

140 cluding heparin, direct thrombin inhibitors [dabigatran etexilate], and heparins) causing decreasing

141 sorders (standard of care two [2%] of 90 and dabigatran five [3%] of 176).

142 ran for 31,574 patients, data on apixaban vs dabigatran for 13,084 patients, and data on apixaban vs

143 We compared data on rivaroxaban vs dabigatran for 31,574 patients, data on apixaban vs dabi

144 y monitoring the effectiveness and safety of dabigatran for stroke prevention allowed for early insig

145 te a 5-year prospective monitoring system of dabigatran for stroke prevention that may expedite disco

146 Children received dabigatran for up to 12 months, or less if the identifie

147 ype 2 diabetes; a direct antithrombin agent, dabigatran, for reducing stroke and systemic embolism in

148 ificantly higher annual risk of AKI than the dabigatran group for those with a high CHA2DS2-VASc scor

149 1 to 6+ points, the incidence of AKI for the dabigatran group was relatively stable (1.87% to 2.91% p

150 Although dabigatran has a favorable risk-benefit profile compared

151 Dabigatran has similar effects on VTE recurrence and a l

152 care and 38 (22%) of 176 children receiving dabigatran (hazard ratio [HR] 1.15, 95% CI 0.68 to 1.94;

153 requently in patients given rivaroxaban than dabigatran (hazard ratio [HR], 1.20; 95% confidence inte

154 confidence interval, 1.03-1.42; P=0.021) and dabigatran (hazard ratio, 1.27; 95% confidence interval,

155 ciated with a lower risk of GI bleeding than dabigatran (HR, 0.39; 95% CI, 0.27-0.58; P < .001) or ri

156 on with GI bleeding in the very elderly than dabigatran (HR, 0.45; 95% CI, 0.29-0.71) or rivaroxaban

157 ard ratio [HR], 0.35; 95% CI, 0.17-0.72) and dabigatran (HR, 0.48; 95% CI, 0.30-0.77) compared with w

158 Idarucizumab completely reverses dabigatran in >98% of patients regardless of renal funct

159 ted of rivaroxaban in 505 (82%) pregnancies, dabigatran in 36 (6%), apixaban in 50 (8%), and edoxaban

160 for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose asse

161 andomized to receive either phenprocoumon or dabigatran in addition to aspirin for long-term anticoag

162 The absolute treatment benefits and harms of dabigatran in atrial fibrillation can be estimated based

163 The perioperative management of dabigatran in clinical practice is heterogeneous.

164 ensitive detection of the thrombin inhibitor dabigatran in human plasma and whole blood samples, high

165 bsolute benefit and harm from treatment with dabigatran in individual patients with atrial fibrillati

166 city to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A

167 able to reverse the anticoagulant effect of dabigatran in patients who had uncontrolled bleeding (gr

168 darucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH.

169 ucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent m

170 mediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and w

171 Long-term anticoagulation with dabigatran inhibited thrombin and the formation of occlu

172 he risk of major hemorrhage was 28% lower in dabigatran initiators (-35% to -20%) a finding that was

173 Dabigatran is a direct thrombin inhibitor that effective

174 However, dabigatran is associated with a lower risk for intracran

175 Whether dabigatran is associated with a lower risk of acute kidn

176 Among Asians with NVAF, dabigatran is associated with a lower risk of AKI than w

177 In real-world clinical practice, dabigatran is comparable with warfarin in preventing isc

178 Dabigatran is the first oral anticoagulant licensed for

179 Thromboembolic events on dabigatran led to early termination of a randomized cont

180 ate, and 9.2% with mild renal impairment had dabigatran levels >20 ng/ml compared with 8.3% of patien

181 Dabigatran levels were dependent on renal function, age,

182 Although re-elevation of dabigatran levels within 12 to 24 h is more common with

183 L, LAA closure was dominated by warfarin and dabigatran, meaning that it was less effective (8.44, 8.

184 f children treated with standard of care and dabigatran met the composite efficacy endpoint (38 [42%]

185 nts were observed with apixaban (n = 12) and dabigatran (n = 11).

186 ts with NVAF taking rivaroxaban (n = 3,916), dabigatran (n = 5,921), or warfarin (n = 5,251) using da

187 ) related to direct anticoagulants including dabigatran (OAC-ICH).

188 e risk factors, with only the trials testing dabigatran or apixaban including few patients with 1 str

189 onvalvular atrial fibrillation who initiated dabigatran or rivaroxaban between July and November 2012

190 wanted to determine whether prescription of dabigatran or rivaroxaban was occurring in the dialysis

191 2 and discharged on warfarin or NOAC (either dabigatran or rivaroxaban).

192 amin K antagonist (VKA) oral anticoagulants, dabigatran or rivaroxaban, were compared with VKA in ant

193 care (SOC) for >=3 months, or had completed dabigatran or SOC treatment in the DIVERSITY trial (NCT0

194 patients enrolled in Medicare who initiated dabigatran or warfarin for treatment of nonvalvular atri

195 Adults with atrial fibrillation initiating dabigatran or warfarin therapy between November 2010 and

196 ore-matched patients starting treatment with dabigatran or warfarin.

197 nts (TSOACs) that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are eff

198 inhibitors that directly target factor IIa (dabigatran) or Xa (rivaroxaban, apixaban, edoxaban) are

199 h AF were identified who initiated apixaban, dabigatran, or rivaroxaban between October 1, 2010, and

200 o statistically significant relationships in dabigatran- or rivaroxaban-treated patients without a re

201 alization for gastrointestinal bleeding than dabigatran (p = 0.0416), but on-treatment analysis showe

202 nths of treatment occurred in 30 of the 1279 dabigatran patients (2.3%) compared with 28 of the 1289

203 ent termination was significantly shorter in dabigatran patients (8.5 versus 12.0 months; P=0.015).

204 s showed a linear relationship between total dabigatran plasma concentration and diluted thrombin tim

205 l of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics,

206 bidities, higher CHADS(2) scores, and higher dabigatran plasma levels despite more frequent use of lo

207 The first record of dabigatran prescription among hemodialysis patients occu

208 ation sites with 20 or more patients filling dabigatran prescriptions between 2010 and 2012 for nonva

209 Anticoagulation with dabigatran prevented memory decline, cerebral hypoperfus

210 In covariate adjusted Poisson regression, dabigatran (rate ratio, 1.48; 95% confidence interval, 1

211 sk of hemorrhagic death was even larger with dabigatran (rate ratio, 1.78; 95% confidence interval, 1

212 vels despite more frequent use of lower-dose dabigatran regimens.

213 Concentrations of unbound dabigatran remained below 20 ng per milliliter at 24 hou

214 rate of thrombin, the high concentration of dabigatran required to achieve this effect the in vivo p

215 re fed chow containing either rivaroxaban or dabigatran, respectively.

216 atients on Active Dabigatran), the extent of dabigatran reversal and clinical outcomes were compared

217 ficacy and safety of idarucizumab for urgent dabigatran reversal in patients with major GI bleeding.

218 pen-label, single-arm, prospective cohort of dabigatran reversal were evaluated.

219 quiring urgent procedures by providing rapid dabigatran reversal, and is the only agent of its class

220 gastrointestinal bleeding was similar during dabigatran risk period and non-exposed period (incidence

221 xcept intracranial hemorrhage, in which case dabigatran risk was reduced.

222 ported a relationship between drug levels of dabigatran, rivaroxaban, and apixaban and coagulation as

223 applied to estimate spot volume and quantify dabigatran, rivaroxaban, and apixaban concentrations on

224 Dabigatran, rivaroxaban, and apixaban exhibit variable e

225 measurement of the anticoagulant activity of dabigatran, rivaroxaban, and apixaban.

226 mpare 4 oral anticoagulant agents (apixaban, dabigatran, rivaroxaban, and warfarin) for their effects

227 sed to balance 4 treatment groups (apixaban, dabigatran, rivaroxaban, and warfarin) on 66 baseline ch

228 introduction of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban), many h

229 direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, and edoxaban, provide

230 bolism, compared a novel oral anticoagulant (dabigatran, rivaroxaban, apixaban, or edoxaban) with war

231 odds ratios associated with initiating VKA, dabigatran, rivaroxaban, or apixaban for patients aged >

232 who received at least 1 NOAC prescription of dabigatran, rivaroxaban, or apixaban from January 1, 201

233 trial fibrillation with incident exposure to dabigatran, rivaroxaban, or apixaban from October 1, 201

234 nd arterial embolism in patients who started dabigatran, rivaroxaban, or warfarin.

235 Among dabigatran-, rivaroxaban-, and their VKA-matched-treated

236 in prescription of OAC overall, direct OAC (dabigatran/rivaroxaban/apixaban), and multivariable asso

237 In summary, dabigatran showed a favorable safety profile for seconda

238 Compared with warfarin, both rivaroxaban and dabigatran significantly decreased the risk for ischemic

239 istration of idarucizumab as measured by the dabigatran-specific assays diluted thrombin time and eca

240 ffects of Idarucizumab in Patients on Active Dabigatran), the extent of dabigatran reversal and clini

241 nt idarucizumab for reversing the effects of dabigatran, the investigational factor Xa decoy andexane

242 Comparing high-dose to low-dose dabigatran, the net benefit (absolute risk reduction min

243 Among 25 289 patients starting dabigatran therapy and 25 289 propensity score-matched p

244 ar atrial fibrillation patients treated with dabigatran, there was variability in patient medication

245 hose taking either low-dose or standard-dose dabigatran, those with a warfarin-naive or warfarin-expe

246 opulation, warfarin was prescribed to 88.9%, dabigatran to 9.6%, and rivaroxaban to 1.5%.

247 The study focuses the dose administration of dabigatran to avoid the deaths due to hemorrhagic compli

248 omes according to baseline renal function in dabigatran-treated nondialysis patients receiving idaruc

249 d for shared decision making before starting dabigatran treatment and to determine the optimal dose.

250 In addition, long-term dabigatran treatment significantly reduced the extent of

251 isorders (standard of care three [3%] of 90, dabigatran two [1%] of 176), and gastrointestinal disord

252 confidence interval, 0.48-0.99; P=0.048) and dabigatran use (hazard ratio, 0.66; 95% confidence inter

253 and significance of the association between dabigatran use and myocardial infarction varied in sensi

254 ble analyses adjusted for propensity scores, dabigatran use was associated with a lower risk of bleed

255 Subgroup analysis revealed that among dabigatran users, those taking either low-dose or standa

256 compared with non-exposed period among naive dabigatran users.

257 te the safety of perioperative management of dabigatran using a specified protocol.

258 d directly with warfarin and indirectly with dabigatran, using data from the long-term (mean 3.8 year

259 mination of a randomized controlled trial of dabigatran versus phenprocoumon in left ventricular assi

260 in initiation of rivaroxaban or apixaban or dabigatran versus vitamin K antagonists (VKA) in patient

261 The comparative safety of dabigatran versus warfarin for treatment of nonvalvular

262 nd mortality associated with rivaroxaban and dabigatran versus warfarin in Asians with NVAF.

263 myocardial infarction in patients receiving dabigatran versus warfarin in practice.

264 ients with atrial fibrillation randomised to dabigatran versus warfarin in the RE-LY trial.

265 Trial data for the benefits and risks of dabigatran versus warfarin in the treatment of nonvalvul

266 2015, we conducted 9 sequential analyses of dabigatran versus warfarin users in a sequential cohort

267 , the incidences of stroke and bleeding with dabigatran versus warfarin were consistent with those se

268 AKI in Asians with NVAF who were prescribed dabigatran versus warfarin.

269 detect an increased risk of GI bleeding over dabigatran vs warfarin risk period.

270 The median maximum percentage reversal of dabigatran was 100% (95% confidence interval, 100 to 100

271 he median proportion of patients adherent to dabigatran was 74% (interquartile range [IQR], 66%-80%).

272 of care was 85.0 days (IQR 80.0-90.0) and to dabigatran was 84.5 days (78.0-89.0).

273 In particular, dabigatran was associated with a higher risk of gastroin

274 Dabigatran was associated with a lower risk of AKI than

275 d mortality (HR, 0.68 [0.56-0.83]; P<0.001); dabigatran was associated with a similar risk of stroke

276 Dabigatran was associated with a trend toward lower risk

277 When comparing each NOAC with warfarin, dabigatran was associated with lower risks of >/=30% dec

278 In general practice settings, dabigatran was associated with reduced risk of ischemic

279 The last dose of dabigatran was at 24, 48, or 96 hours before surgery acc

280 The efficacy of both dosages of dabigatran was consistent with the overall trial irrespe

281 Dabigatran was non-inferior to standard of care in terms

282 database of young and healthy participants, dabigatran was not associated with increased incidence r

283 Complete reversal of dabigatran was observed in 118 of 121 patients (97.5%) w

284 lower stroke rates in women taking high-dose dabigatran was observed.

285 Resumption of dabigatran was prespecified according to the complexity

286 Dabigatran was the most common non-VKA OAC (NOAC) (40% u

287 ectiveness ratios compared with warfarin and dabigatran were $20 486 and $23 422 per quality-adjusted

288 among Asians with NVAF, both rivaroxaban and dabigatran were associated with reduced risk for ischemi

289 analysis of RE-LY, plasma concentrations of dabigatran were determined in patients treated with dabi

290 macokinetic/pharmacodynamic relationships of dabigatran were similar to those in adult VTE patients.

291 atio of the acoustic assay demonstrates that dabigatran with FEIBA 50 combination could be a safe rem

292 is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio.

293 ratios (95% confidence intervals) comparing dabigatran with warfarin (reference) were as follows: is

294 any VHD did not influence the comparison of dabigatran with warfarin.

295 ongitudinal, observational studies comparing dabigatran with warfarin.

296 Overall, 203 children received dabigatran, with median exposure being 36.3 weeks (range

297 tage reversal of the anticoagulant effect of dabigatran within 4 hours after the administration of id

298 tage reversal of the anticoagulant effect of dabigatran within 4 hours after the administration of id

299 pletely reversed the anticoagulant effect of dabigatran within minutes.

300 en are more frequently treated with low-dose dabigatran, yet a trend toward lower stroke rates in wom